A new study in the Canadian Medical Association Journal (CMAJ) found no increased risk of autoimmune disorders in girls who received quadrivalent human papillomavirus (HPV4
) vaccination, adding to the body of evidence for the safety of the vaccine.
MONDAY, July 30, 2018 (HealthDay News) -- Following quadrivalent human papillomavirus (HPV4
) vaccination, girls age 12 to 17 years do not have increased risk of autoimmune disorders, according to a study published recently in CMAJ, the journal of the Canadian Medical Association.
The quadrivalent human papillomavirus (HPV4
) vaccine is effective at protecting against 90 percent of the strains that cause cervical and anal cancer.
FDA licensure of quadrivalent human papillomavirus vaccine (HPV4
, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).
Three effective vaccines are approved by the Food and Drug Administration (FDA): the bivalent vaccine (HPV2), which protects against HPV types 16 and 18; the tetravalent vaccine (HPV4
), which protects against types 16, 18, 6, and 11; the 9-valent vaccine (HPV9), which protects against types 6, 11, 16, 18, 31, 33, 45, 52, and 58 [6, 7].
Namely, in sporadic cases of common warts concurrent infections with two or more HPV types can be identified, including their well-known etiological agents, such as HPV1, HPV2, HPV4
, HPV7, HPV27, HPV57, and HPV65 (3, 7, 10, 26, 32).
Licensed in December 2014, HPV9 added 5 high-risk HPV antigens to the quadrivalent HPV vaccine (HPV4
Furthermore, all HPV nomenclature in the 2016 recommendations will be updated to reflect currently accepted naming formats; for example, HPV4
will now be called 4-valent or 4V HPV In the footnotes, the 9-valent HPV vaccine is now included along with the 5-valent and 4-valent variants, along with restructured language to clarify administration instructions.
for protection against certain HPV viruses, namely, HPV4
and HPV2 vaccines (Markowitz et al., 2014).
Both the quadrivalent (HPV4
) and bivalent (HPV2) vaccines protect against HPV types 16 and 18, which cause 70% of cervical cancers; HPV4
also protects against HPV types 6 and 11, which cause 90% of genital warts (1,2).
* Zoster and human papillomavirus vaccines (either HPV2 or HPV4
) are no longer specifically indicated for health care workers; instead, each should be provided to health care professionals and other patients who meet age and other indications.
Shortly thereafter in 2006, a new tetanus toxoid, diphtheria, and acellular pertussis vaccine (Tdap) was recommended, and in March 2007 the quadrivalent human papillomavirus vaccine (HPV4
: types 6, 11, 16, and 18) was recommended for use in girls, starting at age 11-12 years, and young women up to 26 years of age.